At the same time, neither the use of mortality inhibitors nor ferroptosis related-inhibitors can completely eliminate the effect of ART, indicating that ART has a combined inhibitory effect on ovarian cancer tumor cells in a variety of ways (86).Octreotide, an FDA-approved medication that is commonly used in the clinical treatment of ovarian cancer, can directly decrease the expression of GPX4 inducing ferroptosis (87). Here, GPX4 is linked to neoplasm.